Global Markets Direct’s, 'Recurrent Malignant Glioma - Pipeline Review, H2 2012', provides an overview of the Recurrent Malignant Glioma therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma. 'Recurrent Malignant Glioma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Recurrent Malignant Glioma.- A review of the Recurrent Malignant Glioma
products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Recurrent Malignant Glioma pipeline on the basis of route of administration and molecule type.- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.- Key discontinued pipeline projects.- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Recurrent Malignant Glioma.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Recurrent Malignant Glioma pipeline depth and focus of Recurrent Malignant Glioma therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

PLEASE SELECT A FORMAT

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

EUR 942USD 1,000GBP 662

SITE LICENSE Electronic (PDF)

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

EUR 1414USD 1,500GBP 994

ENTERPRISEWIDE Electronic (PDF)

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

SUPPORT NEPAL

WHY CHOOSE RESEARCH AND MARKETS?

WORLD'S LARGEST SELECTION >Access to over 1,500,000 market research reports.

TRUSTED BY THE BEST >Over 400 of the Fortune 500 buy their research from us.

CUSTOMER FOCUSED >24 / 7 phone and email support.

SAFE & SECURE >Your payment details are protected by us.

KEEP UP TO DATE

ON ALL THE LATEST PRODUCTS

Enter your email address:

TESTIMONIALS

It was a pleasant and smooth experience to buy reports here at Research and Markets. We appreciate Claire's prompt replies and fast delivery of what we ordered. Your company is our top choice to buy market reports from.<br/>Mrs Jennifer WangSecretariat GeneralChina International Trade Institute